Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.27 per share for its common stock, set for payment on April 28, 2023, to stockholders of record by March 31, 2023. Additionally, a quarterly cash dividend of $12.50 per share for the 5.00% Series B Mandatory Convertible Preferred Stock will be paid on April 17, 2023, also to holders of record by March 31, 2023. Danaher focuses on solving complex challenges through its global science and technology initiatives, with a diverse workforce of about 81,000 employees.
Danaher Corporation (NYSE: DHR) announced the creation of a new public entity, Veralto Corporation, expected to launch in Q4 2023. Veralto will encompass Danaher’s Environmental and Applied Solutions (EAS) segment, which generated approximately $4.8 billion in revenue in 2022 and employs about 16,000 individuals. This standalone company will be led by Jennifer L. Honeycutt, Danaher's Executive VP. Veralto aims to list under the symbol VLTO on the New York Stock Exchange and will focus on improving global access to vital resources, including safe food and water. The name reflects the company's commitment to excellence.
Beckman Coulter Diagnostics and MeMed have announced a strategic partnership to enhance the Access Family of Immunoassay Analyzers by integrating the MeMed BV test. This diagnostic tool can differentiate between bacterial and viral infections, addressing overuse and underuse of antibiotics. The MeMed BV test has been validated in studies involving over 20,000 patients, gaining US FDA clearance and CE marking. Beckman Coulter aims to improve patient care and combat antimicrobial resistance through this innovation, with both companies optimistic about the potential healthcare outcomes from this collaboration.
Danaher Corporation (NYSE: DHR) announced its fourth quarter and full year 2022 results, showcasing significant growth. For Q4 2022, net earnings reached $2.2 billion ($2.99 per diluted share), marking a 25% increase year-over-year, while revenues increased by 2.5% to $8.4 billion. For the full year, net earnings totaled $7.1 billion ($9.66 per share), a 13.5% increase, with revenues up 7% to $31.5 billion. Non-GAAP metrics showed improved performance, with adjusted diluted net earnings growing by 6.5% in Q4 and 9% for the full year. The company forecasts mid-single digit growth for Q1 2023. CEO Rainer M. Blair highlighted strong execution and market share gains as key strengths.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present the fourth quarter 2022 financial performance at the J.P. Morgan Healthcare Conference on January 10, 2023. Estimated revenues are expected to rise in the low-single digits year-over-year, with non-GAAP core revenue growth projected in the high-single digits, exceeding previous guidance. Cepheid's molecular diagnostics business has notably contributed over $1 billion in respiratory testing revenues in the quarter. Danaher is optimistic about sustaining long-term shareholder value.
Danaher Corporation (NYSE: DHR) announced that its President and CEO, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. ET. The presentation will be available via a webcast and archived on Danaher’s website. Danaher is a leading global science and technology innovator focused on solving complex challenges in healthcare and environmental markets. With a team of around 80,000 associates, Danaher operates more than 20 companies under its comprehensive business system.
Danaher Corporation (NYSE: DHR) has scheduled a webcast for its fourth quarter 2022 earnings conference call on January 24, 2023, at 8:00 a.m. ET. The duration is expected to be around one hour, during which the company will discuss its financial performance and future expectations. Presentations will be available on their website, and a replay will be accessible shortly after the call. Investors can join by dialing in, and additional details will be provided in the Investors section of Danaher’s website.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on January 27, 2023, to holders of record on December 30, 2022. Additionally, a cash dividend of $12.50 per share on its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on January 15, 2023, to those on record as of December 31, 2022. This dividend announcement underscores Danaher's commitment to returning value to shareholders.
Danaher Corporation (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will present at the Evercore ISI HealthCONx Conference on November 30, 2022, at 10:30 a.m. ET. The presentation will be available via a live webcast on their official website, www.danaher.com.
As a leader in science and technology, Danaher aims to resolve complex challenges while enhancing global quality of life through its innovative solutions.
Cepheid has launched the Xpert Xpress MVP, an FDA-cleared multiplex PCR test that identifies DNA from organisms responsible for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single sample within an hour. This innovation addresses the 10 million annual healthcare visits related to vaginitis in the U.S., enabling more accurate diagnoses and effective treatments while reducing treatment failures and antimicrobial resistance. The test expedites diagnosis, ultimately enhancing patient outcomes in women's health.